HCPLive Network

Simple Reminder Form Increases Pneumococcal Vaccination Rate

 
TUESDAY, Jan. 22 (HealthDay News) -- Use of a simple point-of-care paper reminder form is associated with an increase in the percentage of immunosuppressed rheumatology patients who remain up-to-date with their pneumococcal vaccinations, according to research published in the January issue of Arthritis & Rheumatism.

Sonali P. Desai, M.D., M.P.H., of the Brigham and Women's Hospital in Boston, and colleagues evaluated the effects of a quality improvement strategy involving a paper point-of-care reminder form designed to increase the percentage of immunosuppressed patients who kept up-to-date with pneumococcal vaccination, in a rheumatology practice. The cohort included 3,717 patients who were taking immunosuppressive medications (66.0 percent with rheumatoid arthritis; 74.1 percent women).

The researchers found that, in the time period following the intervention, there was a significant increase in the rate of patients who were up-to-date with pneumococcal vaccination for rheumatologists in the intervention (67.6 to 80.0 percent), compared with a stable rate among rheumatologists in the nonintervention control (52.3 to 52.0 percent). Positive predictors of receiving the appropriate vaccinations including having received the intervention (hazard ratio [HR], 3.58), having a primary care physician affiliated with Brigham and Women's Hospital (HR, 1.68), having a diagnosis of diabetes mellitus (HR, 1.57), and being 56 to 65 years of age at baseline (HR, 1.24).

"It is possible to significantly increase vaccination for an important at-risk immunosuppressed patient population through the use of a simple point-of-care reminder," the authors write. "Future efforts should continue to study and test quality improvement methods in order to effect sustained change."

One author disclosed financial ties to the pharmaceutical industry and UpToDate.
 

Abstract
Full Text

Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
The Advisory Committee on Immunization Practices has released updated adult vaccination recommendations for 2013; these recommendations have been published online Jan. 28 in the Annals of Internal Medicine.
The pneumococcal conjugate vaccine containing 10 serotype-specific polysaccharides conjugated to Haemophilus influenza protein D, tetanus toxoid, and diphtheria toxoid as the carrier proteins is effective against invasive pneumococcal disease, including in infants using a 2+1 schedule, according to a study published online Nov. 16 in The Lancet.
Pediatric rotavirus vaccinations also decrease the prevalence of the disease in unvaccinated adults, according to a study published online Jan. 23 in Clinical Infectious Diseases.
The US Food and Drug Administration has approved the first adjuvanted vaccine for the prevention of H5N1 influenza in adults at greater-than-average risk of exposure, the FDA said.
Currently available evidence indicates the safety of the U.S. childhood immunization schedule, with no indication of major safety concerns, according to a report published Jan. 16 by the Institute of Medicine.
The FDA has granted Bexsero, a meningococcal group B vaccine, breakthrough therapy status.
The prevalence of undervaccination in children is increasing with time, with about half of children undervaccinated before the age of 2 years, and these children have different patterns of health care utilization, according to a study published online Jan. 21 in JAMA Pediatrics.
More Reading